New York, Feb 12, 2026, 15:29 EST — Regular session
Boston Scientific shares rose about 1.2% on Thursday, bucking a broader decline, and last traded at $74.38.
The stock’s relative strength comes on a day when U.S. indexes fell more than 1% as investors sold technology shares and waited for Friday’s U.S. consumer price index report. (Reuters)
Healthcare held up better. The Health Care Select Sector SPDR Fund was up about 0.7%, while the SPDR S&P 500 ETF was down roughly 1.0%.
Boston Scientific closed down 1.1% on Wednesday, lagging some large-cap medical device peers in a mixed session. (MarketWatch)
The recent swings have kept attention on the company’s electrophysiology franchise — products used in minimally invasive procedures to treat heart rhythm disorders — after a sharp selloff last week. (Reuters)
On Feb. 4, the company posted quarterly sales in that segment below some analyst expectations and forecast a slower pace of growth for 2026, pushing the stock down as much as 17% in the session, its steepest one-day percentage drop in more than 25 years. Citi analyst Joanne Wuensch said investors’ worries were “not misplaced,” while CEO Michael Mahoney said he was “really pleased” with the unit’s growth and expects to outpace the broader electrophysiology market. (Reuters)
Boston Scientific has projected 2026 net sales growth of about 10.5% to 11.5%. It also gave an “organic” growth range — a company term that strips out currency swings and some acquisition and divestiture effects. (Boston Scientific)
A regulatory filing earlier this month showed Mahoney exercised options and sold shares under a pre-established Rule 10b5-1 plan. (SEC)
In Thursday’s session, Stryker shares were up about 1.3% and Medtronic added roughly 0.7%.
But the setup cuts both ways. If Boston Scientific’s next updates show the electrophysiology business or its Watchman stroke-prevention device is losing momentum, investors could again question the company’s growth profile after last week’s reset.
For now, traders are watching Friday’s CPI report for the next push on rates expectations — and whether defensive sectors like healthcare keep attracting money if the tech-led selloff deepens. (Ft)
